Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Difficult-to-treat doesn't always mean drug-resistant. A growing body of evidence shows that many patients with immune-mediated inflammatory diseases (IMIDs) continue to suffer from pain, fatigue, and cognitive symptoms even after inflammation is well-controlled — and rheumatology needs a new playbook to address it. Experts are calling for a holistic, interprofessional approach rooted in neurobiology, empathy, and better patient communication.
Rheumatology has made extraordinary strides in suppressing inflammation, but a significant subset of patients — the so-called difficult-to-treat (D2T) population — remain unwell even after their inflammation is brought under control. Experts are pushing back against the notion that D2T simply means drug-resistant, arguing that persistent symptoms like pain, fatigue, sleep disturbance, and cognitive complaints are biologically real and deserve dedicated clinical attention.
The emerging science of the brain-immune axis helps explain why. Central sensitization, altered sensory processing, and impaired pain modulation can drive ongoing symptoms independently of peripheral inflammation. For too long, these patients have been dismissed with a label of "fibromyalgia" and little else — a paradigm that leading rheumatologists say must change. Empathy and clear neurobiologic explanations are now being recognized as foundational first steps in care.
Key Takeaways:
Why it matters: As targeted therapies continue to advance, rheumatology's next frontier is caring for patients whose inflammation is controlled but whose quality of life is not. Addressing this gap requires rethinking clinical models, embracing neurobiology, and leading with empathy.
